Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...

Immune checkpoint (IC) inhibitor drug holidays are safe in patients with ... or metastatic melanoma who were treated at least 6 months with an immunotherapy based on anti–programmed death ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

Approved drugs are statins, PCSK9 Inhibitors ... The rationale for TRML’s TED program with an IL-6 inhibitor is that, as the company says, they have “identified a substantial body of published ...

Few rigorous studies have examined biologic drugs as first-line treatment in ... Five patients started the IL-6 inhibitor tocilizumab (Actemra). In the group initiating conventional DMARDs ...

Synthetic Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States ...

This is where kinase inhibitors come into play. Kinases have become one of the most extensively targeted enzymes in drug development ... all target CDK4/6. However, CDK4/6 inhibitors have their ...

The primary endpoint for many trials of drugs to treat RA is a 20% improvement in the majority of a set of disease criteria defined by the American College of Rheumatology (i.e., the ACR20 response).

Though safety concerns have led some drugmakers to shy away from so-called JAK inhibitors, the startup says it’s found ... On Monday, it closed a $95 million series C round and said the Food and Drug ...

The Jak STAT pathway has been implicated in BCL-2 and interleukin 10 (IL-10 ... drugs under investigation act to inflict severe DNA damage to cancerous cells, thus triggering cellular senescence.

The results of this RCT support our hypothesis that immunosuppressive drugs can be used to prevent and treat the hyperinflammatory phase of COVID-19. The observational studies for corticosteroids and ...